Want to see FR:AB full AI Analyst Report?
AB Stock Chart & Stats
€1.48
€0.14(8.88%)
At close: 4:00 PM EST
€1.48
€0.14(8.88%)
Day’s Range― - ―
52-Week Range€0.56 - €1.73
Previous CloseN/A
Volume459.42K
Average Volume (3M)323.75K
Market Cap
€44.83M
Enterprise Value€55.46M
Total Cash (Recent Filing)€10.18M
Total Debt (Recent Filing)€4.24M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Sep 25, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding73,251,990
10 Day Avg. Volume89,975
30 Day Avg. Volume323,750
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)-5.48
Price to Sales (P/S)80.33
P/FCF Ratio-20.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€1.20M
Bulls Say, Bears Say
Bulls Say
Modest, Improving Revenue GrowthRevenue growth across 2023–2025, with 2025 up ~14%, shows improving top-line traction versus prior years. Sustained revenue expansion supports development funding, reduces sole reliance on external capital, and improves the odds of reaching commercial viability over a multi‑quarter horizon.
Sharp Reduction In DebtMaterial decline in reported debt lowers near-term solvency and interest-pressure risk, improving balance-sheet flexibility. This reduction meaningfully eases refinancing needs and creates headroom to prioritize R&D or partnership investments without immediate debt service constraints.
Diversified Small‑molecule Pipeline (masitinib)A single small‑molecule (masitinib) pursued across multiple therapeutic areas increases strategic optionality: multiple indication pathways, licensing or partnership opportunities, and less binary dependency on one market. Diversification in indications supports durable value creation if programs progress.
Bears Say
Persistently Negative Shareholder EquityNegative equity reflects cumulative losses and a weakened capital base, constraining access to traditional financing and increasing reliance on dilutive raises or milestone funding. This structural weakness heightens solvency sensitivity to further operating setbacks over months.
Return To Significant Cash Burn In 2025After a rare positive year, cash burn resumed materially in 2025, signaling recurring funding needs. Persistent negative operating and free cash flow elevates liquidity risk, increasing probability of near‑term financing rounds that could dilute shareholders or constrain R&D pacing.
Deep, Sustained UnprofitabilityChronic, sizable operating and net losses relative to revenue indicate the business remains far from break‑even. Sustained unprofitability undermines internal funding of development programs and makes long‑term viability dependent on successful trial outcomes or ongoing external capital.
AB Science SA News
AB FAQ
What was AB Science SA’s price range in the past 12 months?
AB Science SA lowest stock price was €0.56 and its highest was €1.73 in the past 12 months.
What is AB Science SA’s market cap?
AB Science SA’s market cap is €44.83M.
When is AB Science SA’s upcoming earnings report date?
AB Science SA’s upcoming earnings report date is Sep 25, 2026 which is in 65 days.
How were AB Science SA’s earnings last quarter?
AB Science SA released its earnings results on May 13, 2026. The company reported -€0.07 earnings per share for the quarter, the consensus estimate of -€0.07 by €0.
Is AB Science SA overvalued?
According to Wall Street analysts AB Science SA’s price is currently Overvalued.
Does AB Science SA pay dividends?
AB Science SA does not currently pay dividends.
What is AB Science SA’s EPS estimate?
AB Science SA’s EPS estimate is -0.07.
How many shares outstanding does AB Science SA have?
AB Science SA has 73,251,990 shares outstanding.
What happened to AB Science SA’s price movement after its last earnings report?
AB Science SA reported an EPS of -€0.07 in its last earnings report, expectations of -€0.07. Following the earnings report the stock price went down -3.32%.
Which hedge fund is a major shareholder of AB Science SA?
Currently, no hedge funds are holding shares in FR:AB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AB Science SA
AB Science S.A. is a pharmaceutical company dedicated to the discovery, development, and commercialization of protein kinase inhibitors for applications in both human and animal health. Its primary drug candidate, masitinib, a tyrosine kinase inhibitor, is currently undergoing late-stage (Phase III) clinical investigations for a range of serious conditions including prostate cancer, pancreatic cancer, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Alzheimer's disease, severe asthma, and mastocytosis. Additionally, masitinib is being evaluated in Phase II clinical trials for the treatment of Covid-19. The company's pipeline also features AB8939, a synthetic microtubule destabilizer aimed at treating acute myeloid leukemia, and AB20001, which is in Phase 2 trials to assess the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients experiencing moderate to severe COVID-19. Masitinib is sold under the brand name Masivet in the European market. AB Science S.A. was founded in 2001 and is based in Paris, France.